The increasing knowledge of barrier tissue-resident memory macrophages and trained innate immunity (TII) will help develop both nontarget-specific and target-specific TII-based vaccine strategies.

Light Chain Bioscience, a clinical-stage biotechnology company advancing the next generation of bispecific antibodies to treat cancer, today presented positive results from a Phase 1/1b study of ...

Novel combination including eftilagimod alfa (efti) in neoadjuvant setting drives 51.5% tumour hyalinization/fibrosis in patients with soft ...

Novel combination of efti with KEYTRUDA® and chemotherapy generates strong response rates across all PD-L1 expression levels in first line ...

ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX ...

BioNTech won’t proceed with further development of its BNT111 cancer vaccine candidate in a specific late-stage refractory ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, /PRNewswire/ -- ...

New research into bowel cancer has identified ways to reactivate the immune system to help tackle the spread of the condition.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing ...

The frozen ground beneath our feet holds secrets from thousands of years past. These permanently frozen soils, known as ...

Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies ...